期刊文献+

吲哚美辛微观结晶机制及纳米包衣的影响 被引量:3

Microcosmic mechanisms of amorphous indomethacin crystallization and the influence of nano-coating on crystallization
原文传递
导出
摘要 药物的无定形状态比晶态具有更大的溶解度,可以促进吸收,提高口服生物利用度,但是稳定性差,易转变为晶体状态。本文采用偏光显微镜、扫描电子显微镜、差示扫描量热法、X-射线衍射法和拉曼光谱法等研究无定形吲哚美辛的微观结晶机制,并对药物表面进行喷金包衣,厚度为10 nm,研究结晶行为变化。结果发现,无定形吲哚美辛自由表面的结晶速率远大于其内部,金包衣可显著抑制自由表面的结晶。这提示,自由表面的结晶是影响无定形药物稳定性的关键因素,纳米包衣可用于增强无定形药物的稳定性。 Amorphous drugs have higher solubility,better oral bioavailability and are easier to be absorbed than their crystalline counterparts.However,the amorphous drugs,with weak stability,are so easy to crystallize that they will lose the original advantages.Polarization microscope,scanning electron microscope,differential scanning calorimetry,X-ray diffractomer and Raman spectroscopy were used to study the microcosmic crystallization mechanisms of amorphous indometacin and the performance of the drug crystals.The results showed that the growth rate of amorphous indometacin crystals at the free surface was markedly faster than that through the bulk,and that the crystal growth rate decreased observably after spraying an ultrathin melting gold(10 nm) at the free surface of the drug.These results indicated that the high growth rates of amorphous drugs crystals at the free surface were the key to their stability and that an ultrathin coating could be applied to enhance the stability of amorphous drugs.
出处 《药学学报》 CAS CSCD 北大核心 2011年第6期707-712,共6页 Acta Pharmaceutica Sinica
基金 国家大学生创新性实验计划(101063514) 重庆市自然科学基金项目(CSTC2009BB5106) 中央高校基本科研业务费专项资金资助(XDJK2009C076) 西南大学博士基金项目(SWUB2008032)
关键词 无定形 结晶 表面 纳米包衣 吲哚美辛 amorphou crystallization surface nano-coating indomethacin
  • 相关文献

参考文献1

二级参考文献24

  • 1Rolf H. Polymorphism in the Pharmaceutical Industry [M]. Weinheim: WlLEY-VCH Verlag GmbH & Co. KgaA Press, 2000:259-281.
  • 2Kerc J, Srcic S, Mohar M, et al. Some physicochemical properties of glassy felodipine [J]. Int J Pharm, 1991, 68: 25-33.
  • 3Johari GP, Ram S, Astl G .Characterizing amorphous and microcrystalline solids by calorimetry [J]. J Non-Cryst Solids, 1990, 116: 282-285.
  • 4Mishima O, Calvert LD, Whalley E. An apparently firstorder transition between two amorphous phases of ice induced by pressure [J]. Nature, 1985, 314: 76-78.
  • 5Chokshi R J, Zia H, Sandhu HK, et al. Improving the dissolution rate of poorly water soluble drug by solid dispersion and solid solution: pros and cons [J]. Drug Deliv, 2007, 14: 33-45.
  • 6Matsunaga N, Nakamura K, Yamamoto A, et al. Improvement by solid dispersion of the bioavailability of KRN633, a selective inhibitor of VEGF receptor-2 tyrosine kinase, and identification of its potential therapeutic window [J]. Mol Cancer Ther, 2006, 5: 80-88.
  • 7Dharmendra S, William C. Drug polymorphism and dosage form design: a practical perspective [J]. Adv Drug Deliv Rev, 2004, 56: 335-347.
  • 8Albano AA, Phuapradit W, Sandhu HK, et al. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability: US, 6482847[P]. 2002-11-19.
  • 9Shikura T, Ishizawa T, Suemune K, et al. Amorphous substance of tricyclic triazolobenzazepine derivative: US, 7229985 [P]. 2007-06-12.
  • 10Chono S, Takeda E, Seki T, et al. Enhancement of the dissolution rate and gastrointestinal absorption of pranlukast as a model poorly water-soluble drug by grinding with gelatin [J]. Int J Pharm, 2008, 347: 71-78.

共引文献16

同被引文献30

  • 1王志玲,王正,阎昊鹏.麦秆表面自由能及其分量研究[J].高分子材料科学与工程,2007,23(3):207-210. 被引量:18
  • 2Pan X, Tan N, Zeng G, et al. Amentoflavone and its derivatives as novel natural inhibitors of human Cathepsin VB[J]. Bioorg Med Chem, 2005, 13(20):5819-5825.
  • 3Jung HJ, Sung WS, Yeo SH, et al. Antifungal effect of amento-flavone derived from Selaginella tamariscina[J]. Arch Pharm Res, 2006, 29(9):746-751.
  • 4Yin MH, Kang DG, Choi DH, et al. Screening of vasorelaxant activity of some medicinal plants used in Oriental medicines[J]. J Ethnopharmacol, 2005, 99(1):113-117.
  • 5Cardoso CR, de Syllos Clus IM, Bernardi CC, et al. Mutagenic activity promoted by amentoflavone and methanolic extract of Byrsonima crassa Niedenzu[J]. Toxicology, 2006, 225(1):55-63.
  • 6Stegemann S, Leveiller F, Franchi D, et al .When poor solubility becomes an issue: from early stage to proof of concept[J]. Eur J Pharm Sci, 2007, 31(5):249-261.
  • 7Donsi F, Wang Y, Li J, et al. Preparation of curcumin sub-micrometer dispersions by high-pressure homogenization[J]. J Agric Food Chem, 2010, 58(5):2848-2853.
  • 8Kang Y, Wu J, Yin G, et al. Preparation, characterization and in vitro cytotoxicity of indomethacin-loaded PLLA/PLGA microparticles using supercritical CO2 technique[J]. Eur J Pharm Biopharm, 2008, 70(1):85-97.
  • 9Zhang HX, Wang JX, Zhang ZB, et al. Micronization of atorvastatin calcium by antisolvent precipitation process[J]. Int J Pharm, 2009, 374(1/2): 106-113.
  • 10Wang Z,Chen JF,Le Y,et al.Preparation of ultrafine beclomethasone dipropionate drug powder by anti-solvent precipitation[J]. Ind Eng Chem Res, 2007,46(14):4839-4845.

引证文献3

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部